Back ground : Due to recent increases in medical costs and national deficits, effective utilization of limited medical resources is indispensable. Thus, cost-effectiveness of anti-hypertensive treatment is an important social and medical issue in western as well as in eastern countries including Japan. Home blood pressure (HBP) measurements have a stronger predictive power for cardiovascular events than casual clinic blood pressure (CBP) measurements. Therefore, the introduction of HBP measurement for the diagnosis and treatment of hypertension would lead to a decrease in medical expenditures.
Methods : In this study, we investigated the cost-effectiveness of using HBP instead of CBP measurement. To estimate the costs and effects associated with changing from CBP to HBP measurement as the diagnostic tool, we constructed a simulation model (Markov model) using data from the Ohasama study and a national database. The Ohasama study provided the prognostic value of HBP as compared to CBP measurement.
Results : As a result of the cost analysis, the change from CBP to HBP measurement as a diagnostic tool would result in the decrease in medical cost by ¥3.85 trillion in men per 10 years and by ¥6.39 trillion in women per 10 years. Thus, the total reduction was ¥10.24 trillion per 10 years. The reductions in medical costs vary from¥4.64 trillion to¥13.02 million per 10 years, when sensitivity analysis is performed. This is attributable to the reduction of medical costs by avoiding the start of treatment in untreated subjects who are diagnosed as hypertension by CBP but normotension by HBP. Furthermore, it could be expected that adequate BP control mediated by the change in the diagnostic method from CBP to HBP measurement would improve the prognosis for hypertension. In addition, stroke prevention due to adequate BP control based on HBP measurement would lead to decrease the estimates of death as well as stroke incident. If we assume that BP control improves, and systolic blood pressure decreases by 10 mmHg in all patients due to reinforcement of the need for antihypertensive treatment because of the use of HBP measurement, the change from CBP to HBP measurement as a diagnostic tool would result in the extent in living year by 0.001 year per 10 years. On the other hand, the change from CBP to HBP measurement as a diagnostic tool would result in the decrease in the estimate of death and stroke incidence by 12,300 and 40,900, respectively.
Conclusion : Therefore, we conclude that the introduction of HBP measurement for the diagnosis and treatment of hypertension would be very cost-effective. Given the cost savings,extensive application of HBP measurement in the clinical practice of hypertension is expected.
View full abstract